Drug Screen (11 Panel)
CPT Code(s):
80307
Turnaround Time:
8 hours
Specimen Requirements
Preferred Specimen:
Urine
Minimum Volume:
1.0 mL
Transport Container:
Yellow Top Tube or Sterile Cup
Transport Temperature:
Room Temperature
Collection Instructions:
Collect urine in plastic container and transfer to plain yellow top tube (without preservative).
Rejection Criteria:
Specimen received outside stability requirements; Excessive blood, particulates, viscosity present
Stability Criteria
Room Temperature:
24 hours
Refrigerated:
7 days
Frozen:
30 days
Clinical Significance
The Drug Screen (11 Panel) test using immunoassay holds specific clinical significance and diagnostic use in the field of toxicology and substance abuse screening. It is a comprehensive test that detects the presence of multiple drugs or drug classes in a patient's urine, typically using an immunoassay method.
The clinical significance and diagnostic use of the Drug Screen (11 Panel) test include:
1. Substance Abuse Detection: The primary purpose of the Drug Screen (11 Panel) test is to identify the presence of various drugs or drug classes in a patient's urine. The test typically includes screening for commonly abused substances such as opioids, benzodiazepines, amphetamines, cannabinoids, cocaine, barbiturates, methadone, methamphetamine, phencyclidine (PCP), propoxyphene, and tricyclic antidepressants. Detecting the presence of these substances can help diagnose and monitor substance abuse or illicit drug use.
2. Medication Monitoring: The Drug Screen (11 Panel) test also aids in monitoring medication compliance and detecting the misuse or diversion of prescribed medications. For example, it can identify the presence of opioids or benzodiazepines that have been prescribed for pain management or anxiety disorders. Monitoring the use of these medications is essential to ensure patient safety and adherence to prescribed treatment plans.
3. Occupational or Legal Screening: The Drug Screen (11 Panel) test is commonly used for occupational or legal purposes. It is often required by employers to ensure a drug-free workplace, especially in safety-sensitive industries. Additionally, the test may be used in legal settings such as probation or parole programs to monitor compliance with substance use restrictions or treatment plans.
4. Emergency or Acute Care Situations: In emergency or acute care settings, the Drug Screen (11 Panel) test can help healthcare providers assess potential drug intoxication or overdose. It provides rapid information about the presence of drugs that may contribute to a patient's clinical presentation, guiding immediate medical interventions and treatment decisions.
5. Public Health Surveillance: The Drug Screen (11 Panel) test plays a role in public health surveillance programs, enabling the monitoring of drug use trends and patterns within specific populations or geographic regions. This information is valuable for developing targeted prevention and intervention strategies and evaluating the effectiveness of substance abuse programs.
It is important to note that the Drug Screen (11 Panel) test using immunoassay provides rapid screening results but may have limitations in terms of specificity and sensitivity. Confirmatory testing using more specific methods, such as gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-tandem mass spectrometry (LC-MS/MS), is typically performed for positive screening results to confirm the presence of specific drugs and quantify their levels accurately.
In summary, the Drug Screen (11 Panel) test using immunoassay has specific clinical significance in detecting substance abuse, monitoring medication compliance, supporting occupational or legal screening, aiding in emergency or acute care situations, and contributing to public health surveillance. By screening for multiple drugs or drug classes in a patient's urine, this test provides valuable information for clinical decision-making, substance abuse treatment, workplace safety, and public health interventions.